On June 22, 2026, the FDA sent a warning letter, reference CBER 26-728681, to Genzyme Ireland Limited in Waterford, following an inspection conducted between January 12 and January 20 of that year. The subject was significant violations of current good manufacturing practice (CGMP) requirements in the manufacture of licensed biological products. The product in question: Altuviiio, Sanofi’s antihemophilic factor fusion protein indicated for hemophilia A, whose label was expanded as recently as May 10, 2024 to include pediatric bleed-protection data from the Phase 3 XTEND-Kids study. What does this sequence — expanded pediatric approval, then a CGMP breakdown at the manufacturing site, then a warning letter five months into the following year — say about how Sanofi governs the post-approval production of a drug that 152 out of 159 enrolled adults and adolescents in the pivotal trial depended on at therapeutic doses?
The inspection ran eight days. Eight days is not a surprise audit. Inspectors arrived, reviewed processes, issued a Form 483 at the conclusion of the visit, and Genzyme Ireland had the standard 15 business days to respond, per the FDA’s March 2026 draft guidance titled “Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection.” Whatever the response contained, it did not close the loop. Five months later, the FDA converted those observations into a formal warning letter, a step that signals the agency concluded the facility’s corrective commitments were inadequate, incomplete, or structurally unaddressed.
A Pattern Sanofi Already Should Have Recognized
This is not Genzyme’s first time inside a warning letter cycle. On January 15, 2025, the FDA issued a warning letter to Genzyme Corporation, Sanofi’s U.S. subsidiary, for significant deviations from CGMP for active pharmaceutical ingredients at its Framingham, Massachusetts facility. Two warning letters, two Genzyme facilities, 17 months apart. Sanofi’s manufacturing quality function had the Framingham letter in hand while FDA inspectors were boarding a flight to Waterford. The corporate-level corrective action program, whatever it contained, did not extend its reach far enough or fast enough to prevent Ireland from becoming the second entry on the ledger.
That gap is the operational indictment. Under 21 CFR Part 211 and the CGMP framework for licensed biologics, a sponsor bears quality oversight responsibility not just for the site that files the BLA but for every facility in the manufacturing chain. When a subsidiary receives a 483, the parent’s quality system is implicated, not absolved. Sanofi had a live warning letter at one Genzyme node while another node was accumulating the observations that would produce the next one. A functional global quality management system would have triggered a cross-site CGMP audit at every Genzyme facility the moment Framingham received its letter in January 2025.
The product involved sharpens the stakes. Altuviiio is a recombinant fusion protein manufactured through a complex biological process. The FDA’s guidance on Current Good Tissue Practice for HCT/Ps and CGMP expectations for licensed biological products are unambiguous about process control requirements at this level of biological complexity: in-process testing, cell bank integrity, and release criteria are not administrative checkboxes; they are the mechanisms that prevent a contaminated or subpotent lot from reaching a patient with severe hemophilia A who has no viable alternative. The XTEND-Kids trial enrolled children. The updated label covers children. A manufacturing failure at the facility producing this therapy carries a direct line to pediatric patients who cannot buffer a supply disruption or a lot recall the way an oncology patient on a chemotherapy alternative might.
Sanofi has not disclosed the specific 483 observations underlying CBER 26-728681 in any public filing reviewed for this column. That opacity is itself a problem. The FDA publishes warning letters. The underlying 483 observations remain available to the agency, to Sanofi, and to no one else unless a FOIA request forces disclosure. Sponsors who receive 483s are under no obligation to publish them. The clinical operations community, the site investigators prescribing Altuviiio, and the patients currently on therapy therefore have no visibility into what specific manufacturing control failed at Waterford, how long the condition existed before the January 2026 inspection, or whether any released lots were produced under the conditions the FDA cited.
The Post-Approval Oversight Vacuum
The broader structural read here is uncomfortable for the entire biologics manufacturing sector. Approval creates a pressure release. Once the BLA clears, the operational intensity that characterized pre-approval manufacturing validation — the process performance qualification, the continued process verification, the CAPA ladders — tends to flatten into routine. The FDA’s BIMO and CBER inspection programs are the backstop, but they are not a real-time monitoring system. The Waterford inspection covered conditions that almost certainly developed over months, not days. The system found them in January 2026. The warning letter landed in June 2026. Between the manufacturing failure and the warning letter, Altuviiio continued to ship.
The cell therapy manufacturing sector is not operationally over-resourced for this kind of oversight. In 2025, Resilience, a CDMO launched in 2020 specifically to expand biologics manufacturing capacity, closed six underutilized sites after acknowledging it had overbuilt against actual industry demand. Capacity rationalization in the CDMO market means sponsors have fewer external manufacturing partners to stress-test internal quality functions. When a company like Sanofi is running production through wholly owned subsidiaries rather than arms-length CDMOs, the quality oversight accountability is entirely internal, and the Framingham-to-Waterford pattern suggests that internal accountability is not functioning at the system level.
What Has to Change This Quarter
For sponsors: a warning letter at any subsidiary facility should automatically trigger a 90-day cross-site CGMP gap assessment at every facility in the same product family. Not a desk review. A physical audit with independent quality personnel who are not reporting through the same regional management chain as the facility under review. The Framingham letter was a signal. Sanofi’s quality leadership had 17 months to act on it before the Ireland inspection opened. The record suggests they did not act with sufficient urgency or scope.
For FDA-watchers: CBER 26-728681 deserves a FOIA request for the underlying 483 observations. The public has an interest in knowing what specific manufacturing control failures the agency documented at the facility producing a pediatric hemophilia biologic. The warning letter tells us violations occurred. It does not tell us whether any distributed lots were implicated, what in-process controls failed, or whether the facility’s cell banking practices were among the cited observations. Transparency here is not optional; it is the floor of post-market accountability for a drug whose label covers children.
The next signal to watch is Sanofi’s formal response to CBER 26-728681 and whether CBER schedules a re-inspection of the Waterford facility within the standard 12-month follow-up window. If Genzyme Ireland’s corrective action plan receives a close-out letter, the operational question becomes whether Sanofi used the occasion to actually rebuild its global quality governance or simply remediated the observations that made it onto a federal document.
References
- FiercePharma — “Sanofi unit in Ireland chided by FDA over manufacturing flubs linked to Altuviiio”
- FDA — Warning Letter: Genzyme Ireland Limited, CBER 26-728681, June 22, 2026
- Sanofi — “FDA approves updated ALTUVIIIO label with expanded pediatric data,” May 10, 2024
- FDA — Warning Letter: Genzyme Corporation (Framingham, MA), January 15, 2025
- Sanofi — Altuviiio Prescribing Information (Phase 3 XTEND-Kids enrollment and adult/adolescent study data)
- Arnold & Porter — “FDA Issues Guidance on Responding to FDA Form 483s,” March 2026
- FDA — “Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of HCT/Ps” guidance
- BioPharma APAC — “Biopharma Manufacturing: Resilience, Lessons from Capacity Expansion and Supply Chain Resets from 2025”
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
